Adlai Nortye Biopharma has entered into a Global Licensing Agreement with Eisai. Under the terms of the Agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China (“Territory”).   E7046 is an investigational, oral EP4 antagonist with high activity and high selectivity. Based on preliminary results, it is well tolerated in patients with solid tumors. ...